Amgen's Bemarituzumab Phase 3 Success
This is a news story, published by Yahoo Finance, that relates primarily to AMGN news.
AMGN news
For more AMGN news, you can click here:
more AMGN newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Bemarituzumab. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Gastric cancer news, gastric cancers news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
AMGNInsider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
•Health
Health
Amgen (AMGN) Announces Positive Results for Phase 3 Study of Bemarituzumab

74% Informative
Amgen Inc. (NASDAQ: AMGN ) announced positive topline results for an important phase 3 study of Bemarituzumab for certain stomach cancers.
Gastric cancer is the fifth leading cause of cancer-related death globally, with nearly 1 million new cases and over 650,000 deaths each year .
The company announced that the Phase 3 FORTITUDE-101 trial met its primary endpoint.
VR Score
65
Informative language
60
Neutral language
27
Article tone
formal
Language
English
Language complexity
65
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
4
Source diversity
1
Affiliate links
no affiliate links